Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
7.70
+0.27 (3.63%)
Jun 29, 2026, 10:44 AM EDT - Market open
Company Description
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities.
It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need.
Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Instil Bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Bronson Crouch |
Contact Details
Address: 3963 Maple Avenue, Suite 350 Dallas, Texas 75219 United States | |
| Phone | 972 499 3350 |
| Website | instilbio.com |
Stock Details
| Ticker Symbol | TIL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001789769 |
| CUSIP Number | 45783C101 |
| ISIN Number | US45783C2008 |
| Employer ID | 83-2072195 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bronson Crouch | Chairman and Chief Executive Officer |
| Dr. Sandeep Laumas M.D. | Chief Financial Officer and Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 11, 2026 | 8-K | Current Report |
| May 15, 2026 | 10-Q | Quarterly Report |
| May 15, 2026 | 8-K | Current Report |
| Apr 24, 2026 | ARS | Filing |
| Apr 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2026 | 8-K | Current Report |
| Mar 27, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2026 | 10-K | Annual Report |
| Mar 27, 2026 | 8-K | Current Report |